Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17187529 | 1.00 | SIGMAR1 (0.61) | SIGMAR1HTTEPHX1ALDH1A1KDM4E | |
| SCHEMBL17187519 | 1.00 | SIGMAR1 (0.61) | SIGMAR1HTTEPHX1ALDH1A1KDM4E | |
| SCHEMBL18740827 | 0.95 | SIGMAR1 (0.68) | SIGMAR1EPHX1ALDH1A1KDM4E | |
| SCHEMBL19971100 | 0.94 | SIGMAR1 (0.54) | SIGMAR1EPHX1 | |
| SCHEMBL22068841 | 0.92 | SIGMAR1 (0.56) | SIGMAR1EPHX1 | |
| SCHEMBL18230679 | 0.91 | SIGMAR1 (0.54) | SIGMAR1EPHX1ALDH1A1KDM4E | |
| SCHEMBL18230677 | 0.91 | SIGMAR1 (0.54) | SIGMAR1EPHX1ALDH1A1KDM4E | |
| SCHEMBL19971088 | 0.90 | SIGMAR1 (0.58) | SIGMAR1EPHX1 | |
| SCHEMBL12871448 | 0.90 | SIGMAR1 (0.50) | SIGMAR1HTTEPHX1 | |
| SCHEMBL12871445 | 0.90 | SIGMAR1 (0.50) | SIGMAR1HTTEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113265053-A | Catalyst having polysiloxane structural units for curable compositions | SIKA技术股份公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-108473815-B | Catalyst having polysiloxane structural units for curable compositions | SIKA技术股份公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3795649-A2 | CATALYST WITH POLYSILOXANE STRUCTURE UNIT FOR CURABLE COMPOSITIONS | SIKA TECHNOLOGY AG (CH) | 2021-03-24 | — | — | EP | disclosed |
| EP-3294803-B1 | GUANIDINE GROUP CONTAINING CATALYST | SIKA TECH AG (CH) | 2020-12-09 | — | — | EP | disclosed |
| US-10836868-B2 | Catalyst having a polysiloxane structural unit for hardenable compositions | SIKA TECHNOLOGY AG (CH) | 2020-11-17 | — | — | US | disclosed |
| EP-3131992-B1 | FAST CURING MIGRATION-FREE COMPOSITION BASED ON POLYMERS CONTAINING SILANE GROUPS | SIKA TECH AG (CH) | 2020-06-17 | — | — | EP | disclosed |
| US-10414875-B2 | Catalyst containing guanidine groups | SIKA TECHNOLOGY AG (CH) | 2019-09-17 | — | — | US | disclosed |
| US-20180327549-A1 | CATALYST HAVING A POLYSILOXANE STRUCTURAL UNIT FOR HARDENABLE COMPOSITIONS | SIKA TECHNOLOGY AG (CH) | 2018-11-15 | — | — | US | disclosed |
| US-20180148545-A1 | CATALYST CONTAINING GUANIDINE GROUPS | SIKA TECHNOLOGY AG (CH) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414875-B2 | Catalyst containing guanidine groups | GMPS, GMNN, RNMT | SIGMAR1 764/4885HTT 2208/4885EPHX1 2367/4885 |
| US-20180148545-A1 | CATALYST CONTAINING GUANIDINE GROUPS | GMPS, RNMT, GMNN | SIGMAR1 1068/4885HTT 1880/4885EPHX1 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.